BACKGROUND: Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)]. METHODS: We studied 163,490 unique women aged 50-79 years enrolled in Group Health (Washington State) between 1994-2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no). RESULTS: Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (P(trend) ≤ 0.05) for all HT users, except EPT current users (P(trend) = 0.68); DCIS rates did not change in any group. CONCLUSIONS: Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression. IMPACT: Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency.
BACKGROUND: Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)]. METHODS: We studied 163,490 unique women aged 50-79 years enrolled in Group Health (Washington State) between 1994-2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no). RESULTS: Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (P(trend) ≤ 0.05) for all HT users, except EPT current users (P(trend) = 0.68); DCIS rates did not change in any group. CONCLUSIONS: Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression. IMPACT: Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency.
Authors: Andrea Z LaCroix; Rowan T Chlebowski; JoAnn E Manson; Aaron K Aragaki; Karen C Johnson; Lisa Martin; Karen L Margolis; Marcia L Stefanick; Robert Brzyski; J David Curb; Barbara V Howard; Cora E Lewis; Jean Wactawski-Wende Journal: JAMA Date: 2011-04-06 Impact factor: 56.272
Authors: Rowan T Chlebowski; Garnet L Anderson; Margery Gass; Dorothy S Lane; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Marcia L Stefanick; Judith Ockene; Gloria E Sarto; Karen C Johnson; Jean Wactawski-Wende; Peter M Ravdin; Robert Schenken; Susan L Hendrix; Aleksandar Rajkovic; Thomas E Rohan; Shagufta Yasmeen; Ross L Prentice Journal: JAMA Date: 2010-10-20 Impact factor: 56.272
Authors: Terry S Field; Jackie Cernieux; Diana Buist; Ann Geiger; Lois Lamerato; Gene Hart; Don Bachman; Rick Krajenta; Sarah Greene; Mark C Hornbrook; Gary Ansell; Lisa Herrinton; George Reed Journal: J Natl Cancer Inst Date: 2004-01-21 Impact factor: 13.506
Authors: Tracy Onega; Todd MacKenzie; Julia Weiss; Martha Goodrich; Linda Titus-Ernstoff Journal: Cancer Causes Control Date: 2009-10-21 Impact factor: 2.506
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Denise M Boudreau; Janet R Daling; Kathleen E Malone; Jacqueline S Gardner; David K Blough; Susan R Heckbert Journal: Am J Epidemiol Date: 2004-02-01 Impact factor: 4.897
Authors: Karla Kerlikowske; Diana L Miglioretti; Rachel Ballard-Barbash; Donald L Weaver; Diana S M Buist; William E Barlow; Gary Cutter; Berta M Geller; Bonnie Yankaskas; Stephen H Taplin; Patricia A Carney Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: Betsy A Kohler; Elizabeth Ward; Bridget J McCarthy; Maria J Schymura; Lynn A G Ries; Christie Eheman; Ahmedin Jemal; Robert N Anderson; Umed A Ajani; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2011-03-31 Impact factor: 13.506